Showing all 2 results
Nalidixic Tablet
FreeProduct Composition & Strength
We supply this product as Uncoated or Film Coated Tablets. The formulation is engineered for rapid disintegration to ensure the active ingredient is quickly processed for renal excretion.
Active Ingredient Strength (Standard) Therapeutic Role Nalidixic Acid BP/USP 500 mg Quinolone Antibacterial Excipients Q.S. Maize Starch / Gelatin Binder & Disintegrant Coating (Optional) Q.S. HPMC / Titanium Dioxide Film Coating Ondansetron Tablet
FreeProduct Composition & Available Strengths
We supply this critical supportive therapeutic in standard, internationally recognized strengths designed for exact preventative and rescue dosing.
Active Ingredient Available Strengths Primary Clinical Target Ondansetron HCl IP / BP / USP 4 mg Standard Prophylaxis: For moderate emetogenic chemotherapy, general post-operative rescue, and pediatric care. Ondansetron HCl IP / BP / USP 8 mg High-Potency Protection: For highly emetogenic cisplatin-based cancer regimens and severe surgical recovery.
